These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 8891155)

  • 1. In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci.
    Schwalbe RS; McIntosh AC; Qaiyumi S; Johnson JA; Johnson RJ; Furness KM; Holloway WJ; Steele-Moore L
    Antimicrob Agents Chemother; 1996 Oct; 40(10):2416-9. PubMed ID: 8891155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin.
    Harland S; Tebbs SE; Elliott TS
    J Antimicrob Chemother; 1998 Feb; 41(2):273-6. PubMed ID: 9533471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide.
    Biavasco F; Vignaroli C; Lupidi R; Manso E; Facinelli B; Varaldo PE
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2165-72. PubMed ID: 9333042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of a new glycopeptide antibiotic (LY333328) against enterococci and other resistant gram-positive organisms.
    Fraise AP; Andrews J; Wise R
    J Antimicrob Chemother; 1997 Sep; 40(3):423-5. PubMed ID: 9338497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci.
    Nicas TI; Mullen DL; Flokowitsch JE; Preston DA; Snyder NJ; Zweifel MJ; Wilkie SC; Rodriguez MJ; Thompson RC; Cooper RD
    Antimicrob Agents Chemother; 1996 Sep; 40(9):2194-9. PubMed ID: 8878606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracellular activity of vancomycin and Ly333328, a new semisynthetic glycopeptide, against methicillin-resistant Staphylococcus aureus.
    al-Nawas B; Shah PM
    Infection; 1998; 26(3):165-7. PubMed ID: 9646108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae.
    Patel R; Rouse MS; Piper KE; Cockerill FR; Steckelberg JM
    Diagn Microbiol Infect Dis; 1998 Feb; 30(2):89-92. PubMed ID: 9554174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro susceptibility of Staphylococci and Enterococci to vancomycin and teicoplanin.
    Guzek A; Korzeniewski K; Nitsch-Osuch A; Rybicki Z; Prokop E
    Adv Exp Med Biol; 2013; 788():125-32. PubMed ID: 23835969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies.
    Kosowska-Shick K; Clark C; Pankuch GA; McGhee P; Dewasse B; Beachel L; Appelbaum PC
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4217-24. PubMed ID: 19620338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains.
    Rybak MJ; Hershberger E; Moldovan T; Grucz RG
    Antimicrob Agents Chemother; 2000 Apr; 44(4):1062-6. PubMed ID: 10722513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidrug-resistant gram-positive pathogens. An update on current microbiological patterns.
    Marchese A; Debbia EA; Bacca D; Balistreri G; Musolino B; Schito GC
    Drugs; 1997; 54 Suppl 6():11-20. PubMed ID: 9474477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aureus by time-kill curve methods.
    Hershberger E; Aeschlimann JR; Moldovan T; Rybak MJ
    Antimicrob Agents Chemother; 1999 Mar; 43(3):717-21. PubMed ID: 10049300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model.
    Aeschlimann JR; Allen GP; Hershberger E; Rybak MJ
    Antimicrob Agents Chemother; 2000 Nov; 44(11):2991-8. PubMed ID: 11036011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The in-vitro activity of LY333328, a new glycopeptide, against clinical isolates of vancomycin-resistant enterococci.
    Kirk M; Hill RL; Casewell MW; Beighton D
    Adv Exp Med Biol; 1997; 418():483-5. PubMed ID: 9331699
    [No Abstract]   [Full Text] [Related]  

  • 15. In vitro activity and post-antibiotic effect of quinupristin/dalfopristin (Synercid).
    Ling TK; Fung KS; Cheng AF
    Chemotherapy; 2001; 47(4):243-9. PubMed ID: 11399860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative in-vitro evaluation of resistance selection after exposure to teicoplanin, vancomycin, linezolid and quinupristin-dalfopristin in Staphylococcus aureus and Enterococcus spp.
    Drago L; Nicola L; De Vecchi E
    Clin Microbiol Infect; 2008 Jun; 14(6):608-11. PubMed ID: 18397336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative in-vitro activity of quinupristin/dalfopristin against Enterococcus spp.
    Williams JD; Maskell JP; Whiley AC; Sefton AM
    J Antimicrob Chemother; 1997 May; 39 Suppl A():41-6. PubMed ID: 9511061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus faecium.
    Baltch AL; Smith RP; Ritz WJ; Bopp LH
    Antimicrob Agents Chemother; 1998 Oct; 42(10):2564-8. PubMed ID: 9756756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model.
    Allen GP; Cha R; Rybak MJ
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2606-12. PubMed ID: 12121940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibility of staphylococci and enterococci to glycopeptides comparison of 3 test methods.
    Jansen B; Schumacher-Perdreau F; Pulverer G
    Zentralbl Bakteriol; 1995 Oct; 282(4):402-8. PubMed ID: 9810663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.